Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod in relapsing-remitting multiple sclerosis
NCT01742052Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2013
- Primary completion
- Jul 2014
- Countries
- 18
01
Overview
A Phase 2 trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Jan 2013; status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01742052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01742052.